Ionis Pharmaceuticals
$48.519876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$48.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.50 (-1.02%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!
About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Employees
817
Headquarters
Carlsbad, California
Founded
1989
Market Cap
6.52B
Price-Earnings Ratio
23.37
Dividend Yield
—
Average Volume
1.05M
High Today
$49.63
Low Today
$47.95
Open Price
$48.15
Volume
1.03M
52 Week High
$86.58
52 Week Low
$39.32
Collections
Analyst Ratings
48%
of 21 ratings
Buy
48%
Hold
33%
Sell
19%
IONS Earnings
-$0.33
$0.22
$0.78
$1.33
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 7, Pre-Market